Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 tandem 177Lu-DOTATATE and 90Y-DOTATATE in somatostatin receptor-positive neuroendocrine tumors
2011-006234-16Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Mar 2012
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate in apudoma (NET), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Clinical efficacy of treatment. Started Mar 2012; status: completed.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on 2011-006234-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006234-16.